Innovent Biologics announced on December 11, 2025, that its Phase 1b trial of mazdutide (IBI362, a GLP-1/GCG dual agonist) in Chinese adolescents (12-18 years old) with obesity met the primary endpoint, demonstrating significant weight loss and metabolic benefits.1
The trial enrolled 36 participants; mazdutide showed a favorable safety profile with no serious adverse events or discontinuations due to adverse events.1
Innovent plans to initiate a Phase 3 registrational trial for mazdutide in adolescents with obesity or overweight soon, addressing the lack of approved weight-loss drugs for this group in China.1
No information found in search results on Everest acquiring rights to a PCSK9 inhibitor.
Sources:
1. https://www.biospace.com/press-releases/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity